Maternal obesity during pregnancy leads to adipose tissue ER stress in mice via miR-126-mediated reduction in Lunapark.


Journal

Diabetologia
ISSN: 1432-0428
Titre abrégé: Diabetologia
Pays: Germany
ID NLM: 0006777

Informations de publication

Date de publication:
04 2021
Historique:
received: 04 08 2020
accepted: 26 10 2020
pubmed: 28 1 2021
medline: 16 2 2022
entrez: 27 1 2021
Statut: ppublish

Résumé

Levels of the microRNA (miRNA) miR-126-3p are programmed cell-autonomously in visceral adipose tissue of adult offspring born to obese female C57BL/6J mice. The spectrum of miR-126-3p targets and thus the consequences of its dysregulation for adipocyte metabolism are unknown. Therefore, the aim of the current study was to identify novel targets of miR-126-3p in vitro and then establish the outcomes of their dysregulation on adipocyte metabolism in vivo using a well-established maternal obesity mouse model. miR-126-3p overexpression in 3T3-L1 pre-adipocytes followed by pulsed stable isotope labelling by amino acids in culture (pSILAC) was performed to identify novel targets of the miRNA. Well-established bioinformatics algorithms and luciferase assays were then employed to confirm those that were direct targets of miR-126-3p. Selected knockdown experiments were performed in vitro to define the consequences of target dysregulation. Quantitative real-time PCR, immunoblotting, histology, euglycaemic-hyperinsulinaemic clamps and glucose tolerance tests were performed to determine the phenotypic and functional outcomes of maternal programmed miR-126-3p levels in offspring adipose tissue. The proteomic approach confirmed the identity of known targets of miR-126-3p (including IRS-1) and identified Lunapark, an endoplasmic reticulum (ER) protein, as a novel one. We confirmed by luciferase assay that Lunapark was a direct target of miR-126-3p. Overexpression of miR-126-3p in vitro led to a reduction in Lunapark protein levels and increased Perk (also known as Eif2ak3) mRNA levels and small interference-RNA mediated knockdown of Lunapark led to increased Xbp1, spliced Xbp1, Chop (also known as Ddit3) and Perk mRNA levels and an ER stress transcriptional response in 3T3-L1 pre-adipocytes. Consistent with the results found in vitro, increased miR-126-3p expression in adipose tissue from adult mouse offspring born to obese dams was accompanied by decreased Lunapark and IRS-1 protein levels and increased markers of ER stress. At the whole-body level the animals displayed glucose intolerance. Concurrently targeting IRS-1 and Lunapark, a nutritionally programmed increase in miR-126-3p causes adipose tissue insulin resistance and an ER stress response, both of which may contribute to impaired glucose tolerance. These findings provide a novel mechanism by which obesity during pregnancy leads to increased risk of type 2 diabetes in the offspring and therefore identify miR-126-3p as a potential therapeutic target.

Identifiants

pubmed: 33501603
doi: 10.1007/s00125-020-05357-4
pii: 10.1007/s00125-020-05357-4
pmc: PMC7940301
doi:

Substances chimiques

Blood Glucose 0
Homeodomain Proteins 0
Insulin Receptor Substrate Proteins 0
Irs1 protein, mouse 0
Lnpk protein, mouse 0
MIRN126 microRNA, mouse 0
MicroRNAs 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

890-902

Subventions

Organisme : Medical Research Council
ID : MC_UU_12012/4
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UP_A600_1024
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RG/17/12/33167
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/M001636/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00014/5
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00014/4
Pays : United Kingdom

Références

Diabetes. 2011 Jan;60(1):47-55
pubmed: 20943748
Front Neurosci. 2017 Mar 24;11:152
pubmed: 28392758
Diabetes. 2008 Sep;57(9):2438-44
pubmed: 18567819
Cardiovasc Res. 2018 Aug 1;114(10):1372-1384
pubmed: 29635288
Nat Cell Biol. 2012 Jun 24;14(7):707-16
pubmed: 22729086
Diabetes. 2007 Dec;56(12):2910-8
pubmed: 17848624
EMBO Rep. 2006 Sep;7(9):880-5
pubmed: 16953201
Br J Nutr. 2014 Jun 28;111(12):2112-22
pubmed: 24666709
Science. 2004 Oct 15;306(5695):457-61
pubmed: 15486293
Cell. 2009 Feb 20;136(4):642-55
pubmed: 19239886
Int J Obes (Lond). 2018 Apr;42(4):618-624
pubmed: 29158541
Methods Mol Biol. 2011;732:139-52
pubmed: 21431711
Cell. 2013 Apr 25;153(3):516-9
pubmed: 23622238
BMC Med Genomics. 2010 Jan 27;3:3
pubmed: 20105310
Int J Obes (Lond). 2006 Jun;30(6):877-83
pubmed: 16418758
Nat Commun. 2018 Jul 30;9(1):2973
pubmed: 30061690
Mol Metab. 2018 Sep;15:8-19
pubmed: 29773464
Hypertension. 2008 Feb;51(2):383-92
pubmed: 18086952
Int J Obes (Lond). 2015 Apr;39(4):633-41
pubmed: 25640766
Int J Obes (Lond). 2013 Apr;37(4):568-75
pubmed: 22614057
Endocrinology. 2016 Nov;157(11):4246-4256
pubmed: 27583789
BMC Med. 2017 Mar 7;15(1):50
pubmed: 28264723
J Clin Endocrinol Metab. 2007 Jun;92(6):2292-9
pubmed: 17356053
JAMA. 2016 Mar 15;315(11):1129-40
pubmed: 26978208
Proc Natl Acad Sci U S A. 2015 Jan 13;112(2):418-23
pubmed: 25548161
Nature. 2006 Dec 14;444(7121):840-6
pubmed: 17167471
Circulation. 2011 Jul 5;124(1):67-76
pubmed: 21670228
Biochim Biophys Acta. 2013 Dec;1833(12):3460-3470
pubmed: 23850759
Mol Metab. 2014 Jan 20;3(3):325-33
pubmed: 24749062
Autophagy. 2015 Nov 2;11(11):1956-1977
pubmed: 26389781
Int J Obes (Lond). 2016 Feb;40(2):229-38
pubmed: 26367335
Diabetes. 2001 Nov;50(11):2585-90
pubmed: 11679438
Diabetologia. 2008 Aug;51(8):1466-74
pubmed: 18504545
Methods Mol Biol. 2017;1546:149-159
pubmed: 27896764

Auteurs

Juliana de Almeida-Faria (J)

University of Cambridge Metabolic Research Laboratories and MRC Metabolic Diseases Unit, Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK. ju.almeidafaria@gmail.com.
Obesity and Comorbidities Research Center, Faculty of Medical Sciences, State University of Campinas, São Paulo, Brazil. ju.almeidafaria@gmail.com.

Daniella E Duque-Guimarães (DE)

University of Cambridge Metabolic Research Laboratories and MRC Metabolic Diseases Unit, Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK.

Thomas P Ong (TP)

University of Cambridge Metabolic Research Laboratories and MRC Metabolic Diseases Unit, Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK.
Department of Food and Experimental Nutrition, Faculty of Pharmaceutical Sciences, University of São Paulo, Food Research Center, São Paulo, Brazil.

Lucas C Pantaleão (LC)

University of Cambridge Metabolic Research Laboratories and MRC Metabolic Diseases Unit, Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK.

Asha A Carpenter (AA)

University of Cambridge Metabolic Research Laboratories and MRC Metabolic Diseases Unit, Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK.

Elena Loche (E)

University of Cambridge Metabolic Research Laboratories and MRC Metabolic Diseases Unit, Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK.

Laura C Kusinski (LC)

University of Cambridge Metabolic Research Laboratories and MRC Metabolic Diseases Unit, Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK.

Thomas J Ashmore (TJ)

University of Cambridge Metabolic Research Laboratories and MRC Metabolic Diseases Unit, Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK.

Robin Antrobus (R)

Cambridge Institute for Medical Research, University of Cambridge, Hills Road, Cambridge, UK.

Martin Bushell (M)

Cancer Research UK (CRUK), Beatson Institute, Glasgow, UK.

Denise S Fernandez-Twinn (DS)

University of Cambridge Metabolic Research Laboratories and MRC Metabolic Diseases Unit, Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK.

Susan E Ozanne (SE)

University of Cambridge Metabolic Research Laboratories and MRC Metabolic Diseases Unit, Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK. seo10@cam.ac.uk.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH